Table 4.
Some larger randomised trials currently in progress of antichlamydial strategies for prevention of coronary heart disease
| Study | Location | Planned size | Entry criteria | Drugs/duration (months) | Follow up (years) |
|---|---|---|---|---|---|
| ACES* | United States | 4000 | Previous myocardial infarction or coronary revascularisation | Azithromycin/12 | 4 |
| PROVEIT* | United States | 4000 | Acute coronary syndrome | Gatifloxacin/18 | 1.5 |
| WIZARD† | United States | 3800 | Previous myocardial infarction or coronary revascularisation | Azithromycin/3 | 3 |
| MARBLE* | United Kingdom | 1300 | Waiting for coronary artery bypass graft surgery | Azithromycin/3 | 1 |
| STAMINA* | United Kingdom | 600 | Previous myocardial infarction | Azithromycin plus drugs against Helicobacter pylori/0.5 | 1.5 |
*
Patients randomised irrespective of C pneumoniae serostatus.
†
Only patients with C pneumoniae IgG titres ⩾1:16 are to be randomised. In May 2000 WIZARD investigators announced possible enlargement of trial's sample size or longer follow up, or both, to increase its statistical power.